Edition:
United States

Minerva Neurosciences Inc (NERV.OQ)

NERV.OQ on NASDAQ Stock Exchange Global Market

5.55USD
3:59pm EST
Change (% chg)

$0.35 (+6.73%)
Prev Close
$5.20
Open
$5.25
Day's High
$5.60
Day's Low
$5.20
Volume
26,238
Avg. Vol
48,982
52-wk High
$11.15
52-wk Low
$4.90

Latest Key Developments (Source: Significant Developments)

Minerva Neurosciences Names Remy Luthringer As Executive Chairman
Monday, 5 Feb 2018 08:30am EST 

Feb 5 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES NAMES REMY LUTHRINGER AS EXECUTIVE CHAIRMAN AND WILLIAM DOYLE AS LEAD INDEPENDENT DIRECTOR.SAYS CHAIRMAN OF THE BOARD MARC BEER RESIGNED.MINERVA NEUROSCIENCES - WILLIAM DOYLE IS EXECUTIVE CHAIRMAN OF NOVOCURE.  Full Article

Minerva Neurosciences Names Remy Luthringer As Executive Chairman
Monday, 5 Feb 2018 08:30am EST 

Feb 5 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES NAMES REMY LUTHRINGER AS EXECUTIVE CHAIRMAN AND WILLIAM DOYLE AS LEAD INDEPENDENT DIRECTOR.MINERVA NEUROSCIENCES INC - MARC BEER HAS RESIGNED AS CHAIRMAN OF MINERVA'S BOARD OF DIRECTORS.  Full Article

Minerva Neurosciences Announces Enrollment Of First Patient In Phase 2B Trial Comparing Seltorexant Versus Quetiapine
Thursday, 21 Dec 2017 08:00am EST 

Dec 21 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 2B TRIAL COMPARING SELTOREXANT (MIN-202) VERSUS QUETIAPINE AS ADJUNCTIVE THERAPY TO ANTIDEPRESSANTS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER.  Full Article

Minerva Neurosciences Screens First Patient In Phase 3 Trial Of Schizophrenia Drug
Tuesday, 19 Dec 2017 08:00am EST 

Dec 19 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES SCREENS FIRST PATIENT IN PHASE 3 TRIAL OF MIN-101 TO TREAT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA.  Full Article

Minerva Neurosciences Screens First Patient In Phase 3 Trial Of MIN-101 To Treat Negative Symptoms In Schizophrenia
Tuesday, 19 Dec 2017 08:00am EST 

Dec 19 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES SCREENS FIRST PATIENT IN PHASE 3 TRIAL OF MIN-101 TO TREAT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA.MINERVA NEUROSCIENCES INC - ‍ TOP-LINE RESULTS FROM 12-WEEK DOUBLE BLIND PHASE OF TRIAL OF MIN-101 ARE EXPECTED IN FIRST HALF OF 2019​.  Full Article

Minerva Neurosciences names Richard Russell president
Monday, 11 Dec 2017 04:41pm EST 

Dec 11 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES NAMES RICHARD RUSSELL PRESIDENT.MINERVA NEUROSCIENCES INC - REMY LUTHRINGER WILL CONTINUE AS CHIEF EXECUTIVE OFFICER OF MINERVA WHILE RESIGNING HIS POSITION AS PRESIDENT.  Full Article

Minerva Neurosciences reports Q3 loss per share $0.28
Monday, 6 Nov 2017 07:30am EST 

Nov 6 (Reuters) - Minerva Neurosciences Inc :Minerva Neurosciences Inc reports third quarter 2017 financial results and business updates.Q3 loss per share $0.28.Q3 earnings per share view $-0.00 -- Thomson Reuters I/B/E/S.Minerva Neurosciences Inc - ‍expects cash, cash equivalents and marketable securities will be sufficient to fund operations for at least next 12 months​.Minerva Neurosciences Inc - ‍cash, cash equivalents, marketable securities as of Sept 30, were about $143.3 million, compared to $83.0 million as of Dec 31, 2016​.  Full Article

Minerva Neurosciences announces enrollment of first patient in phase 2b trial of seltorexant
Tuesday, 5 Sep 2017 08:00am EDT 

Sept 5 (Reuters) - Minerva Neurosciences Inc ::Minerva Neurosciences announces enrollment of first patient in phase 2b trial of seltorexant (min-202) as adjunctive therapy in patients with major depressive disorder.Minerva Neurosciences Inc - approximately 280 patients are planned to be enrolled at more than 85 clinical sites in U.S., Europe, Russia and Japan.  Full Article

Minerva Neurosciences announces enrollment of first patient in phase 2B trial of Seltorexant
Tuesday, 5 Sep 2017 08:00am EDT 

Sept 5 (Reuters) - Minerva Neurosciences Inc :Minerva Neurosciences announces enrollment of first patient in phase 2B trial of Seltorexant (MIN-202) as adjunctive therapy in patients with major depressive disorder.Approximately 280 patients are planned to be enrolled at more than 85 clinical sites in U.S., Europe, Russia and Japan​.  Full Article

Minerva Neurosciences announces European Commission approval of amendment of MIN-202 agreement with Janssen
Friday, 25 Aug 2017 08:30am EDT 

Aug 25 (Reuters) - Minerva Neurosciences Inc :Minerva Neurosciences announces European Commission approval of amendment of MIN-202 agreement with Janssen.Minerva Neurosciences Inc - ‍combined proceeds are expected to support anticipated data readouts from five planned clinical trials with three product candidates​.Minerva Neurosciences Inc - ‍payments to Minerva by Janssen under new agreement include an upfront payment of $30 million​.Minerva Neurosciences Inc - ‍Minerva has assumed all financial responsibility for phase 3 development costs for MIN-202 in insomnia​.Minerva Neurosciences Inc - ‍Janssen waived remaining payments due from Minerva for phase 2 development of MIN-202, which total approximately $13 million​.Minerva Neurosciences - ‍all Minerva stock previously owned by JJDC will be repurchased by Minerva at par value of $.0001/ share or about $389 in total​.Minerva Neurosciences Inc - ‍under amended agreement, Minerva gains control of development of MIN-202 to treat insomnia​.Minerva Neurosciences Inc - ‍under amended agreement Janssen foregoes its right to royalties on MIN-202 insomnia sales in Minerva territories​.Minerva Neurosciences Inc - ‍ Minerva retains its rights to MIN-202 as adjunctive therapy for major depressive disorder​.  Full Article

BRIEF-Minerva Neurosciences Names Remy Luthringer As Executive Chairman

* MINERVA NEUROSCIENCES NAMES REMY LUTHRINGER AS EXECUTIVE CHAIRMAN AND WILLIAM DOYLE AS LEAD INDEPENDENT DIRECTOR